Lymphoma

Top Story

Pembrolizumab extends PFS in relapsed or refractory classical Hodgkin lymphoma

Pembrolizumab extends PFS in relapsed or refractory classical Hodgkin lymphoma
May 29, 2020

Read the Perspective from Lee Greenberger, PhD

Meeting News

CAR-T shows ‘significant survival benefit’ vs. standard of care in lymphoma subset

May 28, 2020
Axicabtagene ciloleucel induced higher response rates than standard therapies among a subset of patients with lymphoma, according to study results presented at the…
In the Journals

Some childhood cancer survivors at higher risk for pain as adults

May 28, 2020
Certain long-term childhood cancer survivors appeared more likely than their siblings who never had cancer to experience pain as adults, according to a report of the…
Clinical Trials Snapshot

Tisagenlecleucel in primary CNS lymphoma

Cell Therapy Next, May
Phase 1, interventional pilot trial to research the safety of tisagenlecleucel (Kymriah, Novartis) in participants with primary CNS lymphoma.
More Headlines »
CME

Ace the Case: A 65-Year-Old Female With Cough and Shortness of Breath

There is no commercial support for this activity.

More »
Video
Meeting News

Microenvironment signatures show biological subtypes of DLBCL

December 12, 2019
More »
CME

Updates in Diagnosis of PTCL and the Role of CD30

This activity is supported by an educational grant from Seattle Genetics, Inc.

More »